Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.40 |
| ▸ | CAD | P27708 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 2/20 | 0.35 |
| ▸ | METAP1 | P53582 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2953811 | 0.92 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL2953807 | 0.92 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL2953812 | 0.92 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL19216892 | 0.87 | ITGB1 (0.43) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL24374998 | 0.87 | ITGB1 (0.43) | MTNR1AMTNR1BSMN1; SMN2ALDH1A1 | |
| SCHEMBL11773446 | 0.85 | SMN1; SMN2 (0.46) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL11773441 | 0.85 | SMN1; SMN2 (0.46) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL30416798 | 0.83 | CAD (0.40) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL13138368 | 0.81 | SMN1; SMN2 (0.43) | CYP1A2CYP2C9CYP2C19HTTCAD | |
| SCHEMBL21554072 | 0.81 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTCAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332749-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-10-20 | — | — | US | disclosed |
| WO-2022084738-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332749-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | CYP1A2 2286/4885CYP2C9 3286/4885CYP2C19 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.